Details

Autor(en) / Beteiligte

• Okaji, Yurai
• Tsuno, Nelson H
• Tanaka, Minoru
• Yoneyama, Satomi
• Matsuhashi, Mika
• Kitayama, Joji
• Saito, Shinsuke
• Nagura, Yutaka
• Tsuchiya, Takeshi
• Yamada, Jun
• Tanaka, Junichiro
• Yoshikawa, Naoyuki
• Nishikawa, Takeshi
• Shuno, Yasutaka
• Todo, Tomoki
• Saito, Nobuhito
• Takahashi, Koki
• Nagawa, Hirokazu

Titel

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy

Ist Teil von

• European journal of cancer (1990), 2008-02, Vol.44 (3), p.383-390

Ort / Verlag

Oxford: Elsevier Ltd

Erscheinungsjahr

2008

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Vaccines targeting tumour angiogenesis were recently shown to inhibit tumour growth in animal models. However, there is still a lack of information about the clinical utility of anti-angiogenic vaccination. Therefore, here, we aimed to test the clinical effects of a vaccine using glutaraldehyde-fixed human umbilical vein endothelial cells (HUVECs). Six patients with recurrent malignant brain tumours and three patients with metastatic colorectal cancer received intradermal injections of 5 × 107 HUVECs/dose (in total 230 vaccinations). ELISA and flow cytometry revealed immunoglobulin response against HUVECs’ membrane antigens. ELISPOT and chromium-release cytotoxicity assay revealed a specific cellular immune response against HUVECs, which were lysed in an effectors:targets ratio-dependent manner. Gadolinium-contrasted MRI showed partial or complete tumour responses in three malignant brain tumour patients. Except for a DTH-like skin reaction at the injection site, no adverse effect of vaccination could be observed. Our results suggest that the endothelial vaccine can overcome peripheral tolerance of self-angiogenic antigens in clinical settings, and therefore should be useful for adjuvant immunotherapy of cancer.